Arcadia Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
RKDA$0.17+3.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber · Exhibit Description · Form · File No. · Exhibit · FilingDate · FiledHerewith | |||||
| 2.1 | Securities Exchange Agreement dated as of December 4, 2024. | 8-K | 001-37383 | 2.1 | 12/06/2024 |
| 2.2 | First Amendment to Securities and Exchange Agreement dated as of April 25, 2025 | S-4/A | 333-284972 | 2.2 | 7/31/2025 |
| 3.1 | Amended and Restated Certificate of Incorporation of Registrant. | 8-K | 001-37383 | 3.1 | 5/26/2015 |
| 3.2 | Amendment to the Amended and Restated Certificate of Incorporation of Registrant. | 8-K | 001-37383 | 3.1 | 2/28/2023 |
| 3.3 | Certificate of Designation of Series A Preferred Stock. | 8-K | 001-37383 | 3.1 | 12/8/2022 |
| 3.4 | Amended and Restated Bylaws of Registrant. | 8-K | 001-37383 | 3.2 | 5/26/2015 |
| 3.5 | Amendment to the Amended and Restated Bylaws of Registrant. | 8-K | 001-37383 | 3.2 | 12/8/2022 |
| 4.1 | Form of Registrant’s common stock certificate. | S-3 | 333-224061 | 4.1 | 3/30/2018 |
| 4.2 | Form of Investor Warrant. | 8-K | 001-37383 | 4.1 | 12/22/2020 |
| 4.3 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 12/22/2020 |
| 4.4 | Form of Investor Warrant. | 8-K | 001-37383 | 4.1 | 1/29/2021 |
| 4.5 | Form of Placement Agent Warrant. | 8-K | 001-37383 | 4.2 | 1/29/2021 |
| 4.6 | Form of Investor Pre-Funded Warrant. | 8-K | 001-37383 | 4.1 | 8/16/2022 |
| 4.7 | Form of Investor Preferred Investment Option. | 8-K | 001-37383 | 4.2 | 8/16/2022 |
| 4.8 | Form of Placement Agent Preferred Investment Option. | 8-K | 001-37383 | 4.3 | 8/16/2022 |
| 4.9 | Form of Pre-Funded Warrant. | 8-K | 001-37383 | 4.1 | 3/3/2023 |
| 4.10 | Form of Series A Preferred Investment Option. | 8-K | 001-37383 | 4.2 | 3/3/2023 |
| 4.11 | Form of Series B Preferred Investment Option. | 8-K | 001-37383 | 4.3 | 3/3/2023 |
| 4.12 | Form of Placement Agent Preferred Investment Option. | 8-K | 001-37383 | 4.4 | 3/3/2023 |
| 4.13 | Form of Preferred Investment Option. | 8-K | 001-37383 | 4.1 | 1/14/2026 |
| 4.14 | Form of Placement Agent Preferred Investment Option. | 8-K | 001-37383 | 4.4 | 1/14/2026 |
| 4.15 | Description of Registrant’s Securities Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. | 10-K | 001-37383 | 4.7 | 3/28/2024 |
| 10.1* | Form of Indemnification Agreement between the Registrant and each of its Officers and Directors. | S-1 | 333-202124 | 10.7 | 2/17/2015 |
| 10.2* | 2015 Omnibus Equity Incentive Plan and forms of agreement thereunder. | 10-Q | 001-37383 | 10.5 | 8/13/2024 |
| 10.3* | Executive Incentive Bonus Plan. | S-1/A | 333-202124 | 10.15 | 5/11/2015 |
| 10.4* | Amended and Restated Director Compensation Policy. | 10-Q | 001-37383 | 10.14 | 5/10/2016 |
| 10.5* | Form of Severance and Change in Control Agreement. | S-1/A | 333-202124 | 10.18 | 4/6/2015 |
| 10.6* | Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer. | 8-K/A | 001-37383 | 10.1 | 1/5/2023 |
| 10.7 | Form of Registration Rights Agreement. | 8-K | 001-37383 | 10.2 | 3/23/2018 |
| 10.8 | Form of Securities Purchase Agreement dated as of December 18, 2020, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 12/22/2020 |
| 10.9 | Form of Securities Purchase Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 1/29/2021 | |
| 10.10 | Form of Registration Rights Agreement dated as of January 25, 2021, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.2 | 1/29/2021 | |
| 10.11 | Form of Securities Purchase Agreement, dated as of August 12, 2022, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 8/16/2022 | |
| 10.12 | Form of Securities Purchase Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.1 | 3/3/2023 | |
| 10.13 | Form of Registration Rights Agreement dated as of March 2, 2023, between Arcadia Biosciences, Inc. and each purchaser named on the signature pages thereto. | 8-K | 001-37383 | 10.2 | 3/3/2023 | |
| 10.14 | Form of Investment Option Amendment, dated as of March 2, 2023. | 8-K | 001-37383 | 10.3 | 3/3/2023 | |
| 10.15+±** | Asset Purchase Agreement | 8-K | 001-37383 | 10.1 | 5/17/2024 | |
| 10.16+±** | Asset Purchase Agreement | 8-K | 001-37383 | 10.1 | 5/20/2024 | |
| 10.17 | Promissory Note | 8-K | 001-37383 | 10.2 | 5/20/2024 | |
| 10.18 | Security Agreement | 8-K | 001-37383 | 10.3 | 5/20/2024 | |
| 10.19 | Employment Letter and Severance and Change in Control Agreement for Thomas J. Schaefer | 8-K/A | 001-37383 | 10.1 | 8/23/2024 | |
| 10.20 | Employment Letter and Severance and Change in Control Agreement for Mark Kawakami | 8-K/A | 001-37383 | 10.2 | 8/23/2024 | |
| 10.21 | Form of Inducement Letter Agreement dated January 9, 2026. | 8-K | 001-37383 | 10.1 | 1/14/2026 | |
| 19.1 | Insider Trading Disclosure Policy | 10-K/A | 001-37383 | 19.1 | 4/30/2025 | |
| 21.1 | List of subsidiaries of the Registrant. | S-1 | 333-262407 | 21.1 | 1/28/2022 | |
| 23.1 | Consent of Deloitte & Touche LLP, independent registered public accounting firm. | X | ||||
| 24.1 | Power of attorney (included in the signature page to this filing). | X | ||||
| 31.1 · Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | ||||||
|---|---|---|---|---|---|---|
| 31.2 · Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 32.1 · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 32.2 · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. · X | ||||||
| 97.1 | Dodd-Frank Clawback Policy. | 10-K | 001-37383 | 97.1 | 3/28/2024 | |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104.1 | Cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2025, formatted in inline XBRL (and contained in Exhibit 101) | X | ||||
- Indicates a management contract or compensatory plan or arrangement.
- Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as we have determined they (1) are not material and (2) are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy of any omitted portion to the SEC upon request.
± Annexes, schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.
** Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby undertakes to furnish supplemental copies of any of the omitted schedules and exhibits upon request by the SEC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.